Advances in genetic analysis are revolutionising healthcare. Belfast-based Diaceutics is at the forefront of data collection and analysis in this revolution, enabling medical decisions, treatments, practices and products to be tailored to each individual patient.
“The future of precision medicine lies in its consumerisation, giving patients control of their own healthcare,” says Peter Keeling, CEO of Diaceutics, “and the world is moving much faster to that position than the ordinary citizen appreciates.”
The company, which was founded in 2005 and floated on AIM in 2019, has built up a wealth of data containing aggregated testing events and anonymised patient data for over 227 million patients covering approximately 300 diseases. This provides the real world evidence that informs the decision making of more than 35 global pharmaceutical companies across hundreds of precision medicine projects.
It also works with diagnostic testing laboratories to improve their processes. “Our data helps pharmaceutical companies know where the gaps are, and it helps laboratories to know how to close those gaps,” says Keeling.